Biovitrum gets access to Affibody® Technology

Affibody AB today signed a collaboration agreement with Biovitrum AB (publ) (STO:BVT) with the aim of developing new targeted therapeutics for inflammation and autoimmune diseases.

New Technology Broadens Opportunities in Biopharmaceuticals

Through the collaboration Biovitrum gains access to the proprietary technology platforms of Affibody® molecules, as well as the unique albumin-binding technology for pharmaceuticals development. Affibody® molecules are small stable proteins that can have the same effects as large proteins, and in addition have potential efficacy, safety, administration route and price benefits. The albumin-binding technology is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life.

The agreement consists of a defined protein target development collaboration and a product license agreement. Costs associated with the collaboration will be absorbed within Biovitrum´s capped running R&D budget.

"This innovative technology is a strong addition to Biovitrum's biopharmaceuticals and process capabilities. Moreover, the collaboration fits perfectly with our specialist indication focus and strategy", says Peter Edman, CSO of Biovitrum.

"This collaboration with Biovitrum represents an important step in Affibody's efforts to become profitable within the coming two years", says David Bejker, President and CEO of Affibody, "It is the first collaboration with our novel biopharmaceutical concept, based on the Second Generation Affibody® molecules and the Second Generation of our albumin binding technology. We believe that Biovitrum is an ideal partner for the development and commercialization of products based on our technology platforms."